Press Release: Apeing Opens Stage 3 of $APEING Presale at $0.0004 as Project Advances Its 33-Stage Token Sale

Choose a language:

Globe NewsWire News Distribution Service

Details: Written by Globe NewsWire Press Releases; Category: Globe NewsWire News Distribution Service; Published: 13 September 2026; Created: 13 September 2026; Last Updated: 13 September 2026

Stage 3, named Paper Hand Panic, allocates 300 million $APEING tokens as the project reports more than $80,000 raised, 270 holders, and more than 410 million tokens sold

Posted: 2026-09-13 07:30:00

Get Full News Story On GlobeNewsWire Press Release Service

More News From This Category
Press Release: Crypto Price Today Highlights Solana Momentum as Apeing’s New Crypto Presale Stage 3 Almost Sold Out
Sun, 13 Sep 2026 07:07:57 +0000

NEW YORK, Sept. 13, 2026 (GLOBE NEWSWIRE) -- Crypto markets can change direction in a heartbeat. Established networks such as Solana continue attracting attention through ecosystem activity and market developments, while traders also keep an eye on emerging projects entering the market at an earlier stage. That contrast is putting both established tokens and fresh…

Press Release: Build-A-Bear Investor News: If You Have Suffered Losses in Build-A-Bear Workshop, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Sun, 13 Sep 2026 04:08:03 +0000

NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Build-A-Bear Workshop, Inc. (NYSE: BBW) resulting from allegations that Build-A-Bear may have issued materially misleading business information to the investing public.

Press Release: Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Sun, 13 Sep 2026 01:08:05 +0000

Basel, 13 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that its collaborator MediLink released interim results from the randomised phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer (SCLC) who progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor.1…

Press Release: PARK HA DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Park Ha Biological Technology Co., Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH
Sat, 12 Sep 2026 22:08:12 +0000

NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024 and July 8, 2025, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.

Related Bing News Results